Jul. 14, 2025 7:43 AM ETCapricor Therapeutics, Inc. (CAPR) StockCAPRBiotech Pharma Investor888 FollowersSummaryCapricor Therapeutics's dip caused by the Complete Response Letter is a buying opportunity considering the readout of HOPE-3 within 2-3 months.Based on HOPE-2 data and the expected course of Duchenne muscular dystrophy cardiomyopathy, I estimate a very high probability of a positive readout in HOPE-3, at least for cardiac endpoints.CAPR remains well funded through approval, not accounting for milestone payments, future royalty revenue, and a potential Priority Review Voucher worth $150M.The commercial opportunity is large, with no competition for the cardiomyopathy label and potential for a wide mutation-agnostic indication.JOSE LUIS CALVO MARTIN & JOSE ENRIQUE GARCIA-MAURIÑO MUZQUIZThesis OverviewCapricor Therapeutics (NASDAQ:CAPR) is a late-stage pre-commercial biotechnology company. Its lead candidate is deramiocel, currently in phase 3 stage for Duchenne muscular dystrophy (DMD). I have previously covered CAPR giving a "This article was written byBiotech Pharma Investor888 FollowersBackground: Physician involved in clinical research. Investment style: Clinical-stage biotech stocks, long only, both long-term ideas and event-driven trading. My academic/medical background helps me evaluate the scientific fundamentals of biotech stocks.Analyst’s Disclosure:I/we have a beneficial long position in the shares of CAPR either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.CommentsRecommended For You